A combined approach using patch-clamp study and computer simulation study for understanding long QT syndrome and TdP in women

Current Cardiology Reviews

Volumn 4, Issue 4, 2008, Pages 244-250

  Furukawa, Tetsushi ^a   Kurokawa, Junko ^a   Clancy, Colleen E ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Arrhythmia; Long QT syndrome; Nitric oxide; Non genomic pathway; Patch clamp; Sex hormone

Indexed keywords

CALCIUM ION; ESTROGEN; GESTAGEN; IBUTILIDE; POTASSIUM ION; PROGESTERONE; PROGESTERONE RECEPTOR; SEX HORMONE; SODIUM ION;

BETA ADRENERGIC STIMULATION; CALCIUM CURRENT; CARDIOVASCULAR RISK; CELL STIMULATION; COMPUTER ANALYSIS; COMPUTER SIMULATION; DISEASE ACTIVITY; DISEASE COURSE; ELECTROCARDIOGRAPHY; GENE MUTATION; GENOMICS; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INNERVATION; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE POTENTIAL; HEART PROTECTION; HEART REPOLARIZATION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; LONG QT SYNDROME; LUTEAL PHASE; MENSTRUAL CYCLE; MUTATIONAL ANALYSIS; NEUROENDOCRINE SYSTEM; NONHUMAN; PATCH CLAMP; PATHOPHYSIOLOGY; POTASSIUM CURRENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; QT INTERVAL; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT; SODIUM CURRENT; SYMPATHETIC NERVE; TORSADE DES POINTES;

EID: 65649115471     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308786349507     Document Type: Review

References (48)

1. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-2597.
2. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97: 2237-2244.
3. Antzelevitch C, Shimizu W, Yan GX, Sicouri S. Cellular basis for QT dispersion. J Electrocardiol 1998; 30(supple): 168-175.
4. Furukawa T, Kurokawa J. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: Implication for the gender difference in cardiac arrhythmias. Pharmacol Ther 2007; 115: 106-115.
5. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322-1326.
6. Hulot JS, Demolis JL, Riviere R, Strabach S, Christin-Maitre S, Funck-Brentano C. Influence of endogenous oestrogens on QT interval duration. Eur Heart J 2003; 24: 1663-1667.
7. Nakagawa M, Ooie T, Takahashi N, et al. Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol 2006; 29: 607-613.
8. Larsen JA, Tung RH, Sadananda R, et al. Effects of hormone replacement therapy on QT interval. Am J Cardiol 1998; 82: 993-995.
9. Sbarouni E, Zarvalis E, Kyriakides ZS, Kremastinos DT. Absence of effects of short-term estrogen replacement therapy on resting and exertional QT and QTc dispersion in postmenopausal women with coronary artery disease. Pacing Clin Electrophysiol 1998; 21: 2392-2395.
10. Haseroth K, Seyffart K, Wehling M, Christ M. Effects of progestin-estrogen replacement therapy on QT-dispersion in postmenopausal women. Internat J Cardiol 2000; 75: 161-165.
11. Kadish AH, Greenland P, Limacher MC, Frishman WH, Daugherty SA, Schwartz JB. Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol 2004; 9: 366-374.
12. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998; 97: 451-456.
13. Heradien MJ, Goosen A, Crotti L, et al. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341M mutation? J Am Coll Cardiol 2006; 48: 1410-1415.
14. Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000; 6: 224-236.
15. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81: 1269-1304.
16. McKenna NJ, O'Malley BW. Nuclear receptors, coregulators, ligand, and selective receptor modulators: making sense of the patchwork quilt. Ann N Y Acad Sci 2001; 949: 3-5.
17. Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids 2002; 67: 471-475.
18. Losel RM, Falkenstein E, Feuring M, et al. Nongenomic steroid action: controversies, questions, and answer. Physiol Rev 2003; 83: 965-1016.
19. Watson CS, Gametchu B. Proteins of multiple classes may participate in nongenomic steroid actions. Exp Biol Med 2003;; 228: 1272-1281.
20. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Non-transcriptional regulation of cardiac repolarization currents by testosterone. Circulation 2005; 112: 1701-1710.
21. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 2004; 69: 537-542.
22. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87: 677-682.
23. Endoh H, Sasaki H, Maruyama K, et al. Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem Biophys Res Commun 1997; 235: 99-102.
24. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa D. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997; 138: 4030-4033.
25. V4.3 potassium channel gene expression under the control of sex hormones. J Biol Chem 2001; 276: 31883-31890.
26. 2+ channel protein expression by sex hormones. Biochim Biophys Acta 2002; 1569: 59-66.
27. Varró A, Lathrop DA, Hester SB, Nánásai OO, Papp JG. Ionic currents and action potentials in rabbit, rat and guinea pig ventricular myocytes. Basic Res Cardiol 1993; 88: 93-102.
28. Furukawa T, Kurokawa J. Potassium channel remodeling in cardiac hypertrophy. J Mol Cell Cardiol 2006; 41: 753-761.
29. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004; 109: 1826-1833.
30. Nakamura H, Kurokawa J, Bai C-X, et al. Progesterone regulates cardiac repolarization through a nongenomic pathway. An in vitro patch-clamp and computational modeling study. Circulation 2007; 116: 2913-2922.
31. + current in cardiac myocytes. Circ Res 2005; 96: 64-72.
32. 2+ current by ginsenoside Re, an ingredient of Panax ginseng, in guinea-pig cardiomyocytes. Brit J Pharmacol 2004; 142: 567-575.
33. Furukawa T, Bai C-X, Kaihara A, et al. Ginsenoside Re, a main phytosterol of Panax ginseng, activates cardiac potassium channels via a nongenomic pathway of sex hormones. Mol Pharmacol 2006; 70: 1916-1924.
34. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol - Part A: Mol Integ Physiol 2005; 142: 136-143.
35. Yang L, Liu G, Zakharov SI, Bellinger AM, Mongillo M, Marx SO. Protein kinase G phosphorylates Cav1.2 α1c and β2 subunits. Circ Res 2007; 101: 465-474.
36. Hess DT, Matsumoto A, Nudelman R, Stamler JS. S-nitrosylation: spectrum and specificity. Nat Cell Biol 2001; 3: E46-E49.
37. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev 2005; 6: 150-166.
38. i overloaded cardiac myocytes: a simulation study. Biophys J 2000; 78: 2392-2404.
39. Janse de Jonge XA, Boot CR, Thom JM, Ruell PA, Thompson MW. The influence of menstrual cycle phase on skeletal muscle contractile characteristics in humans. J Physiol (Lond) 2001; 530: 161-166.
40. + channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol 2003; 43: 441-461.
41. Reuter H. Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 1983; 301: 569-574.
42. Walsh KB, Kass RS. Regulation of a heart potassium channel by protein kinase A and C. Science 1988; 242: 67-69.
43. Marx SO, Kurokawa J, Reiken S, et al. Requirement of a macro-molecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 2002; 295: 496-499.
44. Terrenoire C, Clancy CE, Cormier JW, Sampson KJ, Kass RS. Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation. Circ Res 2005; 96: e25-34.
45. Kurokawa J, Chen L, Kass RS. Requirement of subunit expression for cAMP-mediated regulation of a heart potassium channel. Proc Natl Acad Sci USA 2003; 100: 2122-2127.
46. Ks function. Nat Genet 1997; 17: 338-340.
47. Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 2005; 26: 119-124.
48. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Internat Med 2006; 259: 59-69.